Cantor Fitzgerald Reiterates Overweight Rating on Lucid Diagnostics Inc (LUCD), Sees Launch in Three New Areas as Favorable and as an Important Commercialization Milestone
Tweet Send to a Friend
Cantor Fitzgerald analyst Charles C. Duncan reiterated an Overweight rating and $12.00 price target on Lucid Diagnostics Inc (NASDAQ: LUCD) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
